A plain-language guide

von Hippel-Lindau disease

What's known, what's still uncertain, and what's actively debated, written plainly, and built only from published medical research.

Early map · 8 sourced statements Every statement names its source Updated 2026-08-04
Please read this first. This guide is a companion to your medical team, not a replacement, and it is not medical advice. Everything here is tied to published research. If something you expected is not here, it almost always means we have not mapped a source for it yet, not that it is unknown to medicine. von Hippel-Lindau disease is an early, growing map, so it will look incomplete on purpose: we would rather show less and have every line be something you can check than fill the page with claims we cannot stand behind. For anything about your own situation, your clinicians hold the full picture. How this guide is built and why.

What's von Hippel-Lindau disease?

Von Hippel-Lindau disease is an inherited tumor-predisposition syndrome caused by changes in the VHL gene, producing benign and malignant tumors across several organs, especially the brain, retina, kidneys, and adrenal glands.

Features mapped4
Treatments mapped2
Published sources3
Last reviewed2026-08-04

Signs and symptoms

Renal cell carcinoma

People with von Hippel-Lindau disease have a high risk of clear cell renal cell carcinoma (a kidney cancer).

Limited evidenceSource: PMID:42313274
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:42306392, ORPHA:892
Notesplain_language confirmed from PMID:42306392 via curation 2026-07-03 [llm:fable-5]. | regrounded primary ORPHA:892 -> PMID:42313274 on 2026-07-03 [Carrie Schluter, BCPA]
Last reviewed2026-07-03

Cerebellar hemangioblastoma

Hemangioblastomas, benign blood-vessel tumors of the brain and spinal cord, are a hallmark of von Hippel-Lindau disease.

Limited evidenceSource: PMID:42313274
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:42010687, ORPHA:892
Notesplain_language confirmed from PMID:42010687 via curation 2026-07-03 [llm:fable-5]. | regrounded primary ORPHA:892 -> PMID:42313274 on 2026-07-03 [Carrie Schluter, BCPA]
Last reviewed2026-07-03

Retinal capillary hemangioma

Blood-vessel tumors can form in the retina (retinal hemangioblastomas) in von Hippel-Lindau disease and can threaten vision.

Limited evidenceSource: PMID:42313274
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:40656908, ORPHA:892
Notesplain_language confirmed from PMID:40656908 via curation 2026-07-03 [llm:fable-5]. | regrounded primary ORPHA:892 -> PMID:42313274 on 2026-07-03 [Carrie Schluter, BCPA]
Last reviewed2026-07-03

Adrenal pheochromocytoma

Pheochromocytomas, tumors of the adrenal gland that can raise blood pressure, occur in von Hippel-Lindau disease.

Limited evidenceSource: PMID:42313274
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41632099, ORPHA:892
Notesplain_language confirmed from PMID:41632099 via curation 2026-07-03 [llm:fable-5]. | regrounded primary ORPHA:892 -> PMID:42313274 on 2026-07-03 [Carrie Schluter, BCPA]
Last reviewed2026-07-03

Treatment and management

What the research describes, not a recommendation. Treatment decisions belong with your clinician.

This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.

belzutifan

Belzutifan is an FDA-approved medicine for von Hippel-Lindau disease that can treat VHL-associated tumors including renal cell carcinoma.

Used to help with: Renal cell carcinoma.

Limited evidenceSource: PMID:41632099
The source text this rests on
“Belzutifan's impact on patients with VHL syndrome, sporadic advanced ccRCC and pheochromocytoma/paraganglioma is discussed, three areas where belzutifan has obtained Food and Drug Administration approval.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:41632099 via curation 2026-07-03
Last reviewed2026-07-03

surgical resection

Surgical removal is the main treatment for hemangioblastomas in von Hippel-Lindau disease.

Used to help with: Cerebellar hemangioblastoma.

Limited evidenceSource: PMID:42264668
The source text this rests on
“The treatment of choice for hemangioblastomas is complete surgical resection.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:42264668 via curation 2026-07-03
Last reviewed2026-07-03

How to read the evidence labels

Widely acceptedSpecialists broadly agree on this.
Strong evidenceBacked by solid, repeated research.
Moderate evidenceReasonable evidence, still being confirmed.
Limited evidenceSome evidence, but not yet convincing.
Early evidenceAn early finding that needs more study.
Experts disagreeResearchers actively disagree about this.
No longer supportedLater, stronger evidence or guidance overturned this.

Where this comes from

This guide is built from 3 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.

PMID:41632099 · Targeting HIF-2α in renal cell carcinoma: Expanding upon belzutifan.
PMID:42264668 · Hemangioblastomas of the Spinal Cord.
PMID:42313274 · Von Hippel-Lindau disease: pathophysiological and clinical advances.

Take it further

Printed, source-linked documents built from this condition's graph — ready to bring to an appointment or attach to a coverage request. Every claim carries its published source, the same as this guide.